25) showed that PDLIM2 repression was associated with lung cancer progression, and poor overall survival (OS), progression free survival (PFS) and post progression survival (PPS) of patients (Fig. 1e–h, Supplementary Fig. 1e, f). Here, PDLIM2 is linked to lung carcinoma.